THE CLINICAL UTILITY OF NOVEL GENOMIC-BASED TEST ON MEDICAL DECISION MAKING FOR THE EVALUATION OF OBSTRUCTIVE CORONARY ARTERY DISEASE IN THE AMBULATORY CARE SETTING
B-5 PHYSICIAN DECISION-MAKING AND TRENDS IN USE OF CARDIAC STRESS TESTING TO DIAGNOSE CORONARY HEART DISEASE IN THE UNITED STATES
H-2 ADHERENCE TO PREVENTIVE PRACTICES AND PROJECTED POPULATION IMPACT OF HEALTH SYSTEM INTERVENTIONS FOR CORONARY HEART DISEASE
B-5 PHYSICIAN DECISION-MAKING AND TRENDS IN USE OF CARDIAC STRESS TESTING TO DIAGNOSE CORONARY HEART DISEASE IN THE UNITED STATES
H-2 ADHERENCE TO PREVENTIVE PRACTICES AND PROJECTED POPULATION IMPACT OF HEALTH SYSTEM INTERVENTIONS FOR CORONARY HEART DISEASE
EFFECT OF WEIGHT LOSS INDUCED BY PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE ON ANNUAL MEDICATION COSTS IN OBESE AND OVERWEIGHT INDIVIDUALS
CHANGES IN ANNUAL MEDICATION COSTS ASSOCIATED WITH WEIGHT LOSS INDUCED BY PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE ACROSS BODY-MASS INDEX LEVELS IN OBESE AND OVERWEIGHT INDIVIDUALS
N-3 EFFECT OF MAGNITUDE OF WEIGHT LOSS ON ANNUAL ANTIHYPERTENSIVE, LIPID-LOWERING, AND ANTIDIABETIC MEDICATION COST IN OBESE AND OVERWEIGHT INDIVIDUALS
CHANGES IN ANNUAL MEDICATION COSTS ASSOCIATED WITH WEIGHT LOSS INDUCED BY PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE ACROSS BODY-MASS INDEX LEVELS IN OBESE AND OVERWEIGHT INDIVIDUALS
N-3 EFFECT OF MAGNITUDE OF WEIGHT LOSS ON ANNUAL ANTIHYPERTENSIVE, LIPID-LOWERING, AND ANTIDIABETIC MEDICATION COST IN OBESE AND OVERWEIGHT INDIVIDUALS